2000 Fiscal Year Final Research Report Summary
The invention of the intellectualization cytokine using a synthetic biological response modifier.
| Project/Area Number |
11672259
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
応用薬理学・医療系薬学
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
KUBO Kazuyoshi Graduate School of Pharmaceutical Sciences Osaka University Associate Professor, 薬学研究科, 助教授 (00028846)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NAKAGAWA Shinsaku Graduate School of Pharmaceutical Sciences Osaka University Associate Professor, 薬学研究科, 助教授 (70207728)
MAYUMI Tadanori Graduate School of Pharmaceutical Sciences Osaka University Professor, 薬学研究科, 教授 (00098485)
|
|---|
| Project Period (FY) |
1999 – 2000
|
| Keywords | Antineoplastic-Agents / Drug-Carriers / Maleic-Anhydrides / Tumor-Necrosis-Factor / 抗腫瘍作用 |
|---|
| Research Abstract |
The purpose of this study is to further explore the usefulness of conjugation with functional polymeric modifiers for clinical application of bioactive proteins and to increase the therapeutic efficacy of tumor necrosis factor alpha (TNF-alpha) by conjugation in vivo. We synthesized TNF-alpha conjugated with the copolymer of divinyl ether and maleic anhydride (DIVEMA), which has intrinsic antitumor activity as a synthetic biological response modifier. The synthesis of DIVEMA-TNF-alpha could be controlled by the addition of 2,3-dimethylmaleic anhydride (DMMAn), which binds to or separates from amino groups when the pH is changed. The specific activity of DIVEMA-TNF-alpha (+) synthesized with DMMAn was hardly decreased in vitro. However, DIVEMA-TNF-alpha (-), which is conjugated without blocking by DMMAn, had a markedly diminished specific activity. DIVEMA-TNF-alpha (+) caused a dramatic hemorrhagic necrotic effect on the tumor when compared to native TNF-alpha 24 h after i.v. injection into mice bearing Sarcoma-180 solid tumors. In addition, DIVEMA-INF-alpha (+) at a dose of only 100 Japan reference units per mouse revealed a dramatic antitumor effect that is approximately 100 times greater than native TNF-alpha and that could induce complete regression in all five mice bearing Meth-A solid tumors without any apparent side effects. Because neither DIVEMA alone nor a mixture of TNF-alpha and DIVEMA caused antitumor activity with i.v. administration, the increase in antitumor potency of TNF-alpha may be caused by the covalent conjugation with DIVEMA.DIVEMA-TNF-alpha at low dose revealed dramatic antitumor potency. Because TNF-alpha injected in vivo is extremely low-dose, concentration of intrinsic TNF-alpha in vivo is not influenced. Therefore, the cytokine network in vivo is not destroyed. These results suggest that DIVEMA is a useful polymeric modifier for conjugation of TNF-alpha to increase its antitumor activity.
|
